Nivolumab Versus Regorafenib in Patients With Hepatocellular Carcinoma After Sorafenib Failure

BACKGROUND: Nivolumab and regorafenib are approved second-line therapies for patients with hepatocellular carcinoma (HCC) after sorafenib failure. This study compared the effectiveness of nivolumab and regorafenib following sorafenib. METHODS: We retrospectively enrolled HCC patients who had undergo...

詳細記述

保存先:
書誌詳細
出版年:Front Oncol
主要な著者: Kuo, Yuan-Hung, Yen, Yi-Hao, Chen, Yen-Yang, Kee, Kwong-Ming, Hung, Chao-Hung, Lu, Sheng-Nan, Hu, Tsung-Hui, Chen, Chien-Hung, Wang, Jing-Houng
フォーマット: Artigo
言語:Inglês
出版事項: Frontiers Media S.A. 2021
主題:
Oncology
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC8201513/
https://ncbi.nlm.nih.gov/pubmed/34136408
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2021.683341
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料